Importantly, a very recent phase II clinical trial testing the safety of blocking this pathway in patients treated with intravenous thrombolysis after ischemic stroke has demonstrated that the PDGFRα antagonist imatinib is both safe and tolerable, and improves neurological outcomes in these patients [66]. The gene discussed is PDGFRA; the disease is ischemic stroke.